MEMORANDUM FOR SGCEE
ATTN: CAPT COLIN GALLAGHER

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled **LPR5 Mutation Case Presentation** presented at/published to **Third Coast Retina, Dallas, TX 23 April 2016** with MDWI 41-108, and has been assigned local file #16148.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

*Warrior Medics – Mission Ready – Patient Focused*
COLIN GALLAGHER, CAPT, 0-3, SGCEE

LPR5 Mutation Case Presentation

MATERIAL IS FOR: ☒ DOMESTIC RELEASE ☐ FOREIGN RELEASE

CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST, ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.

11a. PUBLICATION/JOURNAL (List intended publication/journal.)

11b. PUBLISHED ABSTRACT (List intended journal.)

11c. POSTER (To be demonstrated at meeting; name of meeting, city, state, and date of meeting.)

11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, city, state, and date of meeting.)

Third Coast Retina, Dallas, Tx, on 23 April 2016

11e. OTHER (Describe name of meeting, city, state, and date of meeting.)

DATE
April 22, 2016

59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)
Silva, Debbie, deborah.silva@us.af.mil

14. DUTY PHONE/PAGER NUMBER
210-292-6573

15. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript:

LAST NAME, FIRST NAME AND M.I. GRADE/RANK SQUADRON/GROUP/OFFICE SYMBOL INSTITUTION (If not 59 MDW)

a. Gallagher, Colin 03 59 Trng Squadron/59MDG/SGCEE

17. AUTHOR’S SIGNATURE
GALLAGHER COLIN FRANCIS 11 71271262
March 26, 2016

19. APPROVING AUTHORITY’S PRINTED NAME, RANK, TITLE
Walter Steiglemann, CDR, Ophthalmology Program Director

20. APPROVING AUTHORITY’S SIGNATURE
STEIGLEMAN WALTER R 118693 0137
March 28, 2016
26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: ☒ NO ☐ YES If yes, give date. ☐ N/A
   The presentation is approved.

28. PRINTED NAME, RANK/ GRADE, TITLE OF REVIEWER
   Rocky Calcote, PhD, Clinical Research Administrator

29. REVIEWER SIGNATURE
   CALCOTE ROCKY D 1178245844

30. DATE

31. DATE RECEIVED

32. DATE FORWARDED TO 502 ISG/JAC

33. COMMENTS ☐ APPROVED (In compliance with security and policy review directives.) ☐ DISAPPROVED

34. PRINTED NAME, RANK/ GRADE, TITLE OF REVIEWER

35. REVIEWER SIGNATURE

36. DATE

37. DATE RECEIVED
   19 Apr 2016

38. DATE FORWARDED TO 59 MDW/SGVU
   21 Apr 2016

39. COMMENTS ☒ APPROVED (In compliance with security and policy review directives.) ☐ DISAPPROVED

40. PRINTED NAME, RANK/ GRADE, TITLE OF REVIEWER
   Joe Bela, GS-12, Director, Public Affairs

41. REVIEWER SIGNATURE
   BELA JOE JR. 1130810990

42. DATE
   21 Apr 2016

43. DATE RECEIVED

44. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL
   ☐ YES ☐ NO ☐ COULD NOT BE REACHED ☐ LEFT MESSAGE

45. COMMENTS ☐ APPROVED ☐ DISAPPROVED

46. PRINTED NAME, RANK/ GRADE, TITLE OF REVIEWER

47. REVIEWER SIGNATURE

48. DATE
26. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: ☒ NO ☐ YES If yes, give date: N/A

27. COMMENTS ☒ APPROVED ☐ DISAPPROVED

The presentation is approved.

28. PRINTED NAME, RANK/GRAD, TITLE OF REVIEWER
Rocky Calcote, PhD, Clinical Research Administrator

29. REVIEWER SIGNATURE
CALCOTE ROCKY D 1178245544

33. COMMENTS ☒ APPROVED (In compliance with security and policy review directives.) ☐ DISAPPROVED

Slide presentation includes the disclaimer required by the Joint Ethics Regulation. There are no ethics issues with making this presentation at the Third Coast Retina meeting on 23 April 2016.
HOW OLD?

COLIN GALLAGHER

DISCLOSURES

The views expressed are those of myself, Dr. Gallagher, and do not reflect the official views or policy of the Department of Defense or its Components.
HISTORY OF PRESENT ILLNESS

• Chief Complaint: Decreased red reflex of right eye

• HPI: 3 day old M referred from pediatrics for decreased leukocoria in right eye

HPI CONTINUED

PMHx:
• Term from G2P2
• Uncomplicated SVD
• Denied consanguinity
• (-) infectious screen
• Passed hearing screen

SCHX: Non-contributory

Meds: None

ALL: None

PSHX:
• None
FHX - SISTER AT 4 MO

PHYSICAL EXAM

VA:
- OD: NBTL
- OS: BTL

External Exam:
microphthalmic right eye

3/30/2016
PSLE:

- LLL: Nml OU
- C/S: W & Q OU
- K: Clr & Q OU
- AC: D & Q OU
- I: F & R OU
- L: retrolental opacity OD>OS

DILATED FUNDUS EXAM
LABS

<table>
<thead>
<tr>
<th>Test</th>
<th>Source</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acylcarnitine Panel</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>Amino Acids Profile Neonatal</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>G6PD Gene Mutation Analysis</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>17-Hydroxyprogesterone</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>Cystic Fibrosis Screen</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>Biotinidase Neonatal</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>Thyrotropin Neonatal</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>Hemoglobinopathy</td>
<td>Blood</td>
<td>Normal</td>
</tr>
<tr>
<td>Galactose Neonatal</td>
<td>Blood</td>
<td>Normal</td>
</tr>
</tbody>
</table>

DIFFERENTIAL DIAGNOSIS

- Retinoblastoma
- Retinopathy of prematurity
- Coats disease
- Norrie disease
- X-linked/AD familial exudative vitreoretinopathy
- Persistent fetal vasculature/persistent hyperplastic primary vitreous syndrome
- ATOH7 mutation
FETAL VASCULATURE

- Vessel Regression
- Apoptosis

- Nascent tube
  - proliferation
  - migration
  - lumen formation

- Remodeling
  - matrix remodeling
  - release of inhibition
  - Tie-2 activation

- Vessel destabilization
  - hypoxia
  - injury
  - inflammation
  - neoplasia

M. Elizabeth Harman, MD

STUDIES ON THE PATHOGENESIS OF AVASCULAR RETINA AND NEOVASCULARIZATION INTO THE VITREOUS IN PERIPHERAL SEVERE RETINOPATHY OF PREMATURENESS (AN AMERICAN OPHTHALMOLOGICAL SOCIETY THESIS)

By Mary Elizabeth Harman MD
LITERATURE

Locus for Autosomal Recessive Nonsyndromic Persistent Hyperplastic Primary Vitreous
Shagufa Khalil, Abdul Hamied, Muhammad Ismail, Khalid Atwar, Sari Lercy, Annette M. Payne, Shomi S. Bhattacharya, S. Qasim Meho

LITERATURE

Human Molecular Genetics, 2012, Vol. 21, No. 16 1878-1886
doi:10.1093/hmg/ddl297
Advance Access published on May 24, 2012

ATOH7 mutations cause autosomal recessive persistent hyperplasia of the primary vitreous
Lev Pysoczki1,2, Tehmina Assadi3, Shagufa Khalil4, S. Qasim Meho4, Alysha Abid2, Edward R. Oliver5, Eduardo D. Silva6, Amy Lewanda7, Michael C. Brodsky7, Mark Borchert8, Daniel Keilerman9, Jane C. Sowden10, Mehul T. Dattani11 and Tom Glaser1,2,*
LITERATURE

Visual Acuity Outcomes with and without Surgery in Patients with Persistent Fetal Vasculature

George Alexandrakis, MD, Ingrid U. Scott, MD, MPH, Harry W. Flynn, Jr., MD, Timothy G. Munoz, MD, William J. Feuer, MS

LITERATURE

Infant Aphakia Treatment Study: Effects of persistent fetal vasculature on outcome at 1 year of age

David G. Morrison, MD, a M. Edward Wilson, MD, b Rupal H. Trivedi, MD, MSCR, b Scott R. Lambert, MD, c and Michael J. Lynn, MS, c for the Infant Aphakia Treatment Study Group d
DISCUSSION

- Treatment options?
- Similar presentations?
THANK YOU

Dr. Kim
Dr. Grant
Dr. Harper

REFERENCES